National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Templates® Updated

NCCN has published the following updates to the NCCN Chemotherapy Order Templates (NCCN Templates®):

  • New chemotherapy order templates have been published for Small Cell Lung Cancer to reflect the changes in Version 1.2017 of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer:
    • SCL23 Bendamustine
    • SCL24 Nivolumab
    • SCL25 Nivolumab + Ipilimumab followed by Nivolumab
  • The following template for Small Cell Lung Cancer has been deleted to reflect the changes in Version 1.2017 of the NCCN Guidelines® for Small Cell Lung Cancer:
    • SCL19 Ifosfamide
  • The “Other Supportive Care” section for all nivolumab-containing templates has been updated to include the following updated statement:
    • Nivolumab may cause severe, life-threatening immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated reactions are pneumonitis, colitis, hepatitis, renal failure and nephritis, endocrinopathy, and encephalitis. While most of these reactions occur during treatment, some occur weeks to months after discontinuation of nivolumab. In the setting of immune-mediated reactions, nivolumab may be held, and for severe reactions, nivolumab should be permanently discontinued. High-dose systemic corticosteroid therapy should be initiated for immune-mediated reactions according to specific recommendations in the drug package insert. The recommended corticosteroid dosing, based on the type and severity of reaction, is: Prednisone (or equivalent) 1 – 2 mg/kg daily
  • The “Monitoring and Hold Parameters” section for all nivolumab-containing templates has been updated to include the following new statement:
    • This agent may cause immune-mediated encephalitis and other neurologic disorders.  Signs and symptoms of neurologic deterioration should be monitored as clinically indicated for potential modification or discontinuation. 
  • List of affected templates:
    • Melanoma: MEL22
    • Non-Small Cell Lung Cancer: NSC63
    • Small Cell Lung Cancer: SCL24 and SCL25
  • Indications for the following Colon templates have been changed from “Neoadjuvant or Adjuvant, Advanced or Metastatic” to “Advanced or Metastatic”
    • COL11 CapeOX (Capecitabine/OXALIplatin) + Bevacizumab
    • COL14 FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) + Bevacizumab
    • COL16 mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Bevacizumab
    • COL22 FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) + Cetuximab
    • COL44 mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Cetuximab
    • COL48 mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Panitumumab
    • COL49 FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan + Panitumumab
  • Indications for the following Rectal templates have been changed from “Neoadjuvant or Adjuvant, Advanced or Metastatic” to “Advanced or Metastatic”
    • REC12 Weekly Fluorouracil/Leucovorin + Bevacizumab
    • REC15 FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) + Bevacizumab
    • REC16 mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Bevacizumab
    • REC20 CapeOX (Capecitabine/OXALIplatin) + Bevacizumab
    • REC41 FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) + Cetuximab
    • REC43 Capecitabine + Bevacizumab
    • REC50 Roswell Park Fluorouracil/Leucovorin + Bevacizumab
    • REC51 Simplified Biweekly Infusional Fluorouracil/Leucovorin + Bevacizumab
    • REC61 mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Panitumumab
    • REC62 FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) + Panitumumab

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Templates®, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.com/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)
275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2016 National Comprehensive Cancer Network. All Rights Reserved.